Literature DB >> 25340733

Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort.

Maja Matic1, Elisabeth Norman, Anders Rane, Olof Beck, Maria Andersson, Laure Elens, Dick Tibboel, Vineta Fellman, Ron H N van Schaik.   

Abstract

AIM: Assess association between UGT2B7 polymorphism -900G>A (rs7438135, also known as -842G>A) with morphine kinetics in preterm newborns undergoing mechanical ventilation. MATERIALS &
METHODS: Thirty-four infants were enrolled in a randomized clinical trial and allocated to rapid sequence intubation with remifentanil (1 µg/kg) or morphine (0.3 mg/kg). The latter group was included in our study.
RESULTS: Morphine plasma concentrations at 20 min post intubation were associated with postnatal age (p=0.017) and UGT2B7 -900G>A (p=0.036). UGT2B7 -900A allele carriers (n=13) had lower morphine levels compared with UGT2B7 -900G/G patients (n=2). Morphine-3-glucuronide and morphine-6-glucuronide plasma concentrations were only found to be associated with gestational and postnatal age. However, -900A allele carriers had a higher morphine-3-glucuronide:morphine metabolic ratio compared with patients genotyped as -900G/G (p=0.005), as determined by linear regression.
CONCLUSION: Our small pilot study illustrates that in addition to gestational and postnatal age, the UGT2B7 -900G>A polymorphism significantly alters morphine pharmacokinetics in preterm infants.

Entities:  

Keywords:  UGT2B7; morphine; newborns; pharmacokinetics; polymorphism; ventilation

Mesh:

Substances:

Year:  2014        PMID: 25340733     DOI: 10.2217/pgs.14.115

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  11 in total

Review 1.  Genetics of perioperative pain management.

Authors:  Senthil Packiasabapathy; Nicole Horn; Senthilkumar Sadhasivam
Journal:  Curr Opin Anaesthesiol       Date:  2018-12       Impact factor: 2.706

Review 2.  Neonatal drug therapy: The first frontier of therapeutics for children.

Authors:  K Allegaert; J van den Anker
Journal:  Clin Pharmacol Ther       Date:  2015-07-22       Impact factor: 6.875

Review 3.  Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use.

Authors:  Anne Smits; John N van den Anker; Karel Allegaert
Journal:  J Pharm Pharmacol       Date:  2016-06-30       Impact factor: 3.765

Review 4.  Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy.

Authors:  Joshua C Euteneuer; Suyog Kamatkar; Tsuyoshi Fukuda; Alexander A Vinks; Henry T Akinbi
Journal:  J Clin Pharmacol       Date:  2018-09-11       Impact factor: 3.126

Review 5.  The pharmacogenomics of pain management: prospects for personalized medicine.

Authors:  Sonya Ting; Stephan Schug
Journal:  J Pain Res       Date:  2016-02-10       Impact factor: 3.133

Review 6.  Neonatal pain management: still in search for the Holy Grail.

Authors:  Karel Allegaert; John N van den Anker
Journal:  Int J Clin Pharmacol Ther       Date:  2016-07       Impact factor: 1.366

7.  A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.

Authors:  Astrid W Oosten; João A Abrantes; Siv Jönsson; Maja Matic; Ron H N van Schaik; Peter de Bruijn; Carin C D van der Rijt; Ron H J Mathijssen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 8.  Gender, genetics, and analgesia: understanding the differences in response to pain relief.

Authors:  Senthil Packiasabapathy; Senthilkumar Sadhasivam
Journal:  J Pain Res       Date:  2018-11-08       Impact factor: 3.133

9.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335

Review 10.  Pharmacogenomics and Morphine.

Authors:  Adaku Ofoegbu; Earl B Ettienne
Journal:  J Clin Pharmacol       Date:  2021-06-16       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.